[55] So far, the only clinical study has achieved Delta 32 CCR5 deletion using ZFN-targeted editing to help patients gain partial genetic resistance to R5-tropic HIV-1 infection [56]. This evidence concerns the gene CCR5 and HIV-1 infection.